Suppr超能文献

桥粒芯胶蛋白 3 通过抑制结直肠癌细胞中的 AKT 通路发挥肿瘤抑制活性。

Desmocollin 3 has a tumor suppressive activity through inhibition of AKT pathway in colorectal cancer.

机构信息

Section Pathology of the Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany; Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH, 43210, USA.

Section Pathology of the Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany.

出版信息

Exp Cell Res. 2019 May 15;378(2):124-130. doi: 10.1016/j.yexcr.2019.03.015. Epub 2019 Mar 8.

Abstract

Desmocollin 3 (DSC3) is a transmembrane adhesion protein of desmosomes and involved in carcinogenesis in various cancer types. Downregulation of DSC3 has been reported in colorectal cancer (CRC). However, the function of DSC3 in CRC has not yet been elucidated. In this study, we performed cell-based functional analysis after DSC3 overexpression by stable transfection and knockdown by siRNA in CRC cells. It turned out that overexpression of DSC3 reduced cell proliferation, colony forming ability, induced G0/G1 cell cycle arrest and promoted apoptosis. Further pathway analysis showed that overexpression of DSC3 significantly inhibited the activity of AKT pathway and increased the expression of E-cadherin as well as p53 and p21. In contrast, siRNA-mediated knockdown of DSC3 increased cell proliferation and colony formation, activated the AKT pathway and decreased the expression of E-cadherin as well as p53 and p21. Additionally, in primary CRC patient samples, the expression of DSC3 protein was significantly related to the expression of desmocollin 1 (DSC1) and desmocollin 2 (DSC2) as well as E-cadherin (p < 0.001 respectively). Taken together, our data reveal that DSC3 suppresses CRC cell growth through inhibition of AKT pathway and regulation of E-cadherin. DSC3 may serve as a novel therapeutic target for CRC.

摘要

桥粒胶蛋白 3(DSC3)是桥粒的跨膜黏附蛋白,参与多种癌症类型的癌变。结直肠癌(CRC)中报道了 DSC3 的下调。然而,DSC3 在 CRC 中的功能尚未阐明。在这项研究中,我们通过 CRC 细胞中的稳定转染和 siRNA 敲低后进行了基于细胞的功能分析。结果表明,DSC3 的过表达降低了细胞增殖、集落形成能力,诱导了 G0/G1 细胞周期停滞并促进了细胞凋亡。进一步的通路分析表明,DSC3 的过表达显著抑制了 AKT 通路的活性,增加了 E-钙黏蛋白以及 p53 和 p21 的表达。相比之下,siRNA 介导的 DSC3 敲低增加了细胞增殖和集落形成,激活了 AKT 通路,降低了 E-钙黏蛋白以及 p53 和 p21 的表达。此外,在原发性 CRC 患者样本中,DSC3 蛋白的表达与 DSC1 和 DSC2(分别为 p<0.001)以及 E-钙黏蛋白的表达显著相关。总之,我们的数据表明 DSC3 通过抑制 AKT 通路和调节 E-钙黏蛋白来抑制 CRC 细胞的生长。DSC3 可能成为 CRC 的一种新的治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验